Compugen (CGEN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Compugen Ltd. has announced promising data on the anti-tumor activity and safety of its triple combination therapy involving COM701, COM902, and pembrolizumab in patients with platinum-resistant ovarian cancer. These findings, presented at the Society for Immunotherapy of Cancer Annual Meeting, highlight the potential of COM701 as a differentiated immune checkpoint inhibitor, offering hope for improved treatment options. The company’s confidence in advancing COM701 is bolstered by consistent data from multiple studies, suggesting a unique mechanism of action that may enhance progression-free survival in ovarian cancer patients.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.
